Consortium of iNvestigators of Vascular AnomalieS (CaNVAS)
The Consortium of iNvestigators of Vascular AnomalieS (CaNVAS) is a multi-institutional research consortium founded by a group of pediatric hematologist/oncologists and patient advocacy groups to address the rare nature of vascular anomalies. The need for this consortium stems from the rare nature of these disorders and the paucity of prospective multicentered research in this field, particularly as it relates to novel therapies and outcome studies.
CaNVAS is organized to foster the diffusion and exchange of ideas through scientific meetings, research trials and publications.
Long-term vision and objectives
CaNVAS aims to advance the care of patients, both children and adults, affected by vascular anomalies through the promotion and facilitation of multicentered, collaborative, clinical, translational and outcomes research.
The long-term vision of CaNVAS is to be an internationally recognized collaborative research consortium whose members conduct high-quality clinical and translational research aimed at improving the care of patients with vascular anomalies and related disorders. A consortium objective is the Inclusion of multidisciplinary members from other fields with expertise in the care of patients with vascular anomalies.
Values and goals
The operation of CaNVAS will adhere to the following values: collaboration, credibility, curiosity and commitment to care.
- Collaboration with mutual respect to advance our common goals.
- Ethical standards that maintain accountability for the integrity of our research.
- Fostering and supporting efficiency and productivity of research.
- Design and execution of novel and prospective research in the field.
- A commitment of collective resources to pursue the CaNVAS research goals.
- Advocacy for evidence-based and compassionate care for patients with vascular anomalies.
To develop and execute collaborative, interdisciplinary, clinically related research that will improve clinical care and outcomes of patients with vascular anomalies.
To develop consensus and evidence-based standards to aid in protocol development.
To develop and support funding opportunities for treatment protocols.
To expand CaNVAS research to include prospective translational trials related to new drug development for patients with vascular anomalies.